ARTV (Artiva Biotherapeutics) OCF Yield %: -18.57 (As of Jun. 25, 2026)


ARTV Artiva Biotherapeutics Inc ARTV
12 GF Score
Price $8.63
! 3 Warning Signs
View Full Analysis

What is Artiva Biotherapeutics OCF Yield %?

Artiva Biotherapeutics ARTV -7.30% 12 OCF Yield % is -18.57 as of Jun. 25, 2026. GuruFocus rates ARTV with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,419 Biotechnology companies, Artiva Biotherapeutics ranks worse than 65.26% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Artiva Biotherapeutics's Trailing 12-Month Cash Flow from Operations is $-77.86 Mil, and Market Cap is $419.32 Mil. Therefore, Artiva Biotherapeutics's OCF Yield % for today is -18.57%.

The historical rank and industry rank for Artiva Biotherapeutics's OCF Yield % or its related term are showing as below:

ARTV' s OCF Yield % Range Over the Past 10 Years
Min: -154.11   Med: -45.94   Max: -15.39
Current: -18.57


During the past 7 years, the highest OCF Yield % of Artiva Biotherapeutics was -15.39%. The lowest was -154.11%. And the median was -45.94%.

ARTV's OCF Yield % is ranked worse than
65.26% of 1419 companies
in the Biotechnology industry
Industry Median: -8.46 vs ARTV: -18.57

Artiva Biotherapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Artiva Biotherapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Artiva Biotherapeutics OCF Yield % Related Terms


Artiva Biotherapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Artiva Biotherapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artiva Biotherapeutics OCF Yield % Chart

Artiva Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 -22.47 -72.74

Artiva Biotherapeutics Quarterly Data
Dec19 Dec20 Mar21 Sep21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -108.59 -249.58 -109.03 -55.82 -52.65

ARTV vs ENTA, VNDA, VSTM: OCF Yield % Comparison

For the Biotechnology subindustry, Artiva Biotherapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artiva Biotherapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artiva Biotherapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Artiva Biotherapeutics's OCF Yield % falls into.


ARTV
12GF Score
Artiva Biotherapeutics Inc ARTV
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artiva Biotherapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Artiva Biotherapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-76.751 / 105.51684
=-72.74%

Artiva Biotherapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-20.95 * 4 / 159.17748
=-52.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -18.57 mean?
Artiva Biotherapeutics (ARTV) has a OCF Yield % of -18.57 as of Jun. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Artiva Biotherapeutics and its competitors. According to the industry distribution chart, Artiva Biotherapeutics ranks #926 out of 1419 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Artiva Biotherapeutics' OCF Yield % too high?
Artiva Biotherapeutics' current OCF Yield % is -18.57. Based on the distribution chart, Artiva Biotherapeutics ranks #926 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Artiva Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Artiva Biotherapeutics' OCF Yield % compare to ENTA and VNDA?
According to the Biotechnology industry distribution chart, Artiva Biotherapeutics ranks #926 out of 1419 companies for OCF Yield %. This places Artiva Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Artiva Biotherapeutics and its competitors. Artiva Biotherapeutics's current OCF Yield % is -18.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artiva Biotherapeutics stock overvalued right now?
Artiva Biotherapeutics (ARTV) has a current OCF Yield % of -18.57. The current OCF Yield % is -18.57. Artiva Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Artiva Biotherapeutics (ARTV), the current OCF Yield % is -18.57 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artiva Biotherapeutics Business Description

Address 5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
12GF Score

Get the complete analysis for ARTV

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.63
Price